Target Identification in Lupus (TIL) Grants

The Target Identification in Lupus (TIL) program supports ingenious and determined scientific investigators in their quest to bring new understanding of lupus and ways to treat, prevent, and cure it. The program focuses on identifying novel molecular targets for lupus therapy.

Program Focus:

• Identifying new therapeutic targets in lupus pathogenesis
• Exploring mechanisms of lupus at the molecular level
• Supporting diverse research approaches to understand lupus biology
• Accelerating translation of discoveries toward clinical applications

Geographic Scope: United States (institutions include Yale University, University of Washington, New York University School of Medicine, Brigham and Women's Hospital, University of Massachusetts Medical School, UT Southwestern Medical Center, The Feinstein Institute, and others)

Research Areas Funded:

• Follicular helper T cell targeting
• Cyclic GAMP pathway in SLE
• Interferon-stimulated transcription
• PTPN22 function in B cells
• T cell-B cell interactions
• CXCR3 chemokine axis in cutaneous lupus
• Free glycans and anti-glycan antibodies
• TLR8 and TLR9 signaling
• Neutrophil NETosis
• Antigen presentation pathways

Recent Awardees Examples:

• Joseph Craft, MD (Yale University) - Targeting Follicular Helper T Cells in Lupus
• Keith Elkon, PhD (University of Washington) - The Cyclic GAMO Pathway in SLE
• David Levy, PhD (NYU School of Medicine) - Targeting Interferon-Stimulated Transcription as a Novel Lupus Therapy
• Eric Meffre, PhD (Yale University) - PTPN22 Function in Human B Cells and Inhibition to Reset Tolerance in SLE
• Deepak Rao, MD, PhD (Brigham and Women's Hospital) - Targeting Peripheral T Cell — B Cell Interactions in SLE
• Jillian Richmond, PhD (University of Massachusetts Medical School) - Targeting the CXCR3 Chemokine Axis in Cutaneous Lupus
• Nan Yan, PhD (UT Southwestern Medical Center) - Mammalian Free Glycan, Glycocalyx and Anti-glycan Antibody in Lupus

Application Process

Detailed application procedures and submission requirements are not provided in the available website content. Prospective applicants should visit the Lupus Research Alliance website or contact the organization directly.

Contact for More Information:

• Lupus Research Alliance
• 52 Vanderbilt Ave, Suite 401, New York, NY 10017
• 646-884-6000
• Website: lupusresearch.org